Mark Cuban Cost Plus Drug Company and EmsanaRx Forge Partnership to Make Lower-Cost Medicines Available to Employers
DALLAS, TX; LOUISVILLE, KY, Dec. 08, 2022 (GLOBE NEWSWIRE) -- The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) and EmsanaRx, PBC, the only pharmacy benefit manager (PBM) built by employers, for employers, today announced a collaboration with the launch of EmsanaRx Plus, a first-of-its-kind supplemental drug discount product designed specifically for employers as a standalone pipeline for lower-cost medicines that have been contracted directly with drug manufacturers by Cost Plus Drugs.
- DALLAS, TX; LOUISVILLE, KY, Dec. 08, 2022 (GLOBE NEWSWIRE) -- The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) and EmsanaRx, PBC, the only pharmacy benefit manager (PBM) built by employers, for employers, today announced a collaboration with the launch of EmsanaRx Plus, a first-of-its-kind supplemental drug discount product designed specifically for employers as a standalone pipeline for lower-cost medicines that have been contracted directly with drug manufacturers by Cost Plus Drugs.
- The EmsanaRx Plus supplemental drug discount product represents a transition for Cost Plus Drugs from operating exclusively in the direct-to-consumer market into the employer market, which provides health benefits for roughly half of all Americans.
- “Like Cost Plus Drugs, EmsanaRx is working to disrupt the current pharmacy supply chain to eliminate the unnecessary markup and profiteering that is burdening businesses and consumers with high drug costs,” said Mark Cuban.
- The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) aims to fundamentally change the way the pharmaceutical industry operates.